Keyword | CPC | PCC | Volume | Score | Length of keyword |
---|---|---|---|---|---|
ipilimumab nivolumab | 1.95 | 0.9 | 8251 | 63 | 20 |
ipilimumab | 1.49 | 0.1 | 2996 | 55 | 10 |
nivolumab | 0.12 | 0.7 | 9041 | 77 | 9 |
Keyword | CPC | PCC | Volume | Score |
---|---|---|---|---|
ipilimumab nivolumab | 0.49 | 0.2 | 8957 | 7 |
ipilimumab nivolumab melanoma | 0.94 | 1 | 608 | 81 |
ipilimumab nivolumab mesothelioma | 1.5 | 0.6 | 5121 | 8 |
ipilimumab nivolumab renal cell carcinoma | 1.41 | 0.1 | 4922 | 98 |
ipilimumab nivolumab rcc | 0.28 | 0.8 | 4890 | 37 |
ipilimumab nivolumab nsclc | 1.25 | 0.6 | 256 | 69 |
ipilimumab nivolumab nebenwirkungen | 1.19 | 1 | 2506 | 78 |
ipilimumab nivolumab dosierung | 0.03 | 0.1 | 9693 | 100 |
ipilimumab nivolumab cco | 0.24 | 0.4 | 1654 | 84 |
ipilimumab nivolumab bijwerkingen | 0.01 | 0.4 | 6370 | 39 |
ipilimumab nivolumab fachinfo | 0.71 | 0.2 | 3394 | 77 |
ipilimumab nivolumab macmillan | 0.46 | 0.4 | 8815 | 47 |
ipilimumab nivolumab cabozantinib sarcoma | 0.79 | 0.4 | 4799 | 100 |
ipilimumab nivolumab checkpoint inhibitors | 0.32 | 0.5 | 9357 | 7 |
ipilimumab nivolumab melanoma trial | 0.51 | 0.9 | 7773 | 79 |
ipilimumab and nivolumab | 1.77 | 0.6 | 9551 | 17 |
nivolumab combined with ipilimumab | 0.35 | 1 | 2742 | 89 |
ipilimumab and nivolumab side effects | 1.98 | 0.5 | 6817 | 42 |
nivolumab and ipilimumab therapy | 1.06 | 0.7 | 8817 | 21 |
ipilimumab + nivolumab | 0.02 | 0.7 | 6491 | 38 |